The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 108, Issue 10, Pages 2153-2163
Publisher
Springer Nature
Online
2013-05-10
DOI
10.1038/bjc.2013.212
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
- (2012) X. Liao et al. CLINICAL CANCER RESEARCH
- BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis
- (2012) Matthew F. Kalady et al. DISEASES OF THE COLON & RECTUM
- Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma
- (2012) L.C. Krol et al. EUROPEAN JOURNAL OF CANCER
- KRAS Mutation Status and Clinical Outcome of Preoperative Chemoradiation With Cetuximab in Locally Advanced Rectal Cancer: A Pooled Analysis of 2 Phase II Trials
- (2012) Sun Young Kim et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
- (2011) S. Ogino et al. CLINICAL CANCER RESEARCH
- PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis
- (2011) Arantza Fariña Sarasqueta et al. CELLULAR ONCOLOGY
- The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status
- (2010) A. M. Dahlin et al. CLINICAL CANCER RESEARCH
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
- (2010) Jolien Tol et al. EUROPEAN JOURNAL OF CANCER
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- A Prospective Cohort Study Shows Unique Epigenetic, Genetic, and Prognostic Features of Synchronous Colorectal Cancers
- (2009) Katsuhiko Nosho et al. GASTROENTEROLOGY
- Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma
- (2009) Ki-Seok Jang et al. HISTOPATHOLOGY
- PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
- (2009) Salvatore Siena et al. JNCI-Journal of the National Cancer Institute
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
- (2009) Andrea Sartore-Bianchi et al. PLoS One
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival
- (2008) Hirozumi Sawai et al. BMC GASTROENTEROLOGY
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases
- (2008) L. Barault et al. CANCER RESEARCH
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started